Free Newsletter
SPOTLIGHT: Valeant sells development programs
Valeant Pharmaceuticals has sold the rights to its HIV and cancer development programs to Ardea Biosciences. Report
Valeant Pharmaceuticals has sold the rights to its HIV and cancer development programs to Ardea Biosciences. Report